Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xeris Biopharma Holdings's total inventories for the quarter that ended in Mar. 2026 was €64.2 Mil. Xeris Biopharma Holdings's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €61.4 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Xeris Biopharma Holdings's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €-0.94.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Xeris Biopharma Holdings's Days Inventory for the
three
months ended in Mar. 2026 was 612.82.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Xeris Biopharma Holdings's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xeris Biopharma Holdings's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.85.
Xeris Biopharma Holdings (STU:2B30) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Xeris Biopharma Holdings's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xeris Biopharma Holdings's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Xeris Biopharma Holdings Total Inventories Related Terms
Xeris Biopharma Holdings Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Xeris Biopharma Holdings (STU:2B30) has a Total Inventories of €64.2 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Xeris Biopharma Holdings and its competitors.
Is Xeris Biopharma Holdings' Total Inventories too high?
Xeris Biopharma Holdings' current Total Inventories is €64.2 Mil. Overall, Xeris Biopharma Holdings has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Total Inventories compare to PAHC and PRGO?
Xeris Biopharma Holdings' Total Inventories of €64.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Xeris Biopharma Holdings and its competitors. Xeris Biopharma Holdings's current Total Inventories is €64.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (STU:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.55, compared to a current price of €7.23 — trading 58.9% above its estimated fair value. The current Total Inventories is €64.2 Mil. Xeris Biopharma Holdings' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Xeris Biopharma Holdings (STU:2B30), the current Total Inventories is €64.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (STU:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €7.23 is trading 58.9% above its estimated GF Value™ of €4.55.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for STU:2B30:
Total Inventories: €64.2 Mil
GF Value™: €4.55 vs. price of €7.23 (58.9% above fair value)
No single metric tells the full story. See the STU:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
74GF Score
Get the complete analysis for STU:2B30
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2B30 has been successfully added to your 
